S&P Futures
4,568.50 +5.50 (+0.12%) Dow Futures
35,493.00 +48.00 (+0.14%) Nasdaq Futures
16,072.50 +24.50 (+0.15%) Russell 2000 Futures
1,801.60 +4.60 (+0.26%) Crude Oil
76.74 +0.33 (+0.43%) Gold
2,049.10 +9.10 (+0.45%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 81.98 |
| Open | 82.68 |
| Bid | 33.01 x 800 |
| Ask | 92.98 x 900 |
| Day's Range | 81.21 - 83.81 |
| 52 Week Range | 72.26 - 95.26 |
| Volume | |
| Avg. Volume | 278,375 |
| Market Cap | 4.131B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 32.69 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for HAE
Related Research
- Haemonetics CorporationHAE: Lowering target price to $87.00HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $87.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.RatingFair ValueEconomic Moat7 days agoArgus Research
- CNW Group
OPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS
OpSens Inc. ("OpSens" or the "Corporation") (TSX: OPS) (OTCQX: OPSSF) announces that the Québec Superior Court (the "Court") issued an interim order (the "Interim Order") on October 31, 2023 in connection with the previously announced acquisition by Haemonetics Corporation ("Haemonetics") (NYSE: HAE), a global healthcare company, and 9500-7704 Québec Inc., a wholly-owned subsidiary of Haemonetics ("AcquireCo" and, collectively with Haemonetics, the "Purchaser Parties") of all of the issued and o
- PR Newswire
Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website.
- PR Newswire
Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash tra
